Sep 14, 2021 12:36 JST

Source: Eisai

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021

TOKYO, Sep 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that presentations on a series of abstracts highlighting updates on its oncology products and pipeline will be given at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, from September 16 to 21, 2021, including its in-house discovered lenvatinib mesylate (product name: LENVIMA, an orally available multi-kinase inhibitor, "lenvatinib") and eribulin mesylate (product name: HALAVEN, a halichondrin class microtubule dynamics inhibitor, "eribulin").

At this congress, differences in outcomes by histology and prior therapy in the pivotal Phase 3 Study 309/KEYNOTE-775 trial, which compared the combination therapy of lenvatinib plus pembrolizumab (product name: KEYTRUDA), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), with TPC (Treatment of Physician's Choice) in patients with advanced endometrial cancer, following at least one prior platinum-based regimen, will be presented as an oral presentation (Abstract No: 726MO). In addition, a subgroup analysis and safety update from the pivotal Phase 3 CLEAR study (Study 307/KEYNOTE-581), which compared the combination of lenvatinib plus pembrolizumab versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC) will be presented as an e-poster presentation (Abstract No: 660P).

Additionally, e- poster presentations will be given on the outcomes of early clinical studies on a liposomal formulation of eribulin plus nivolumab (Abstract No: 980P), a CREB-binding protein (CBP)/β-catenin interaction inhibitor E7386 (Abstract No: 473P) and a compound derived from total synthesis of halichondrin, E7130 (Abstract No: 545P).

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

For more information, visit https://www.eisai.com/news/2021/pdf/enews202173pdf.pdf.

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
September 28 2021 10:37 JST
 
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
September 27 2021 13:50 JST
 
Eisai to Join The Global Environmental Initiative "RE100"
September 14 2021 16:46 JST
 
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"
September 13 2021 15:37 JST
 
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
August 31 2021 08:42 JST
 
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma
August 16 2021 09:07 JST
 
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)
August 12 2021 08:31 JST
 
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards
August 05 2021 10:45 JST
 
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures
August 02 2021 11:24 JST
 
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
July 30 2021 09:07 JST
 
More Press release >>

Latest Press Release


More Latest Release >>